The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non‑small cell lung cancer (Review)
- Authors:
- Yao Chen
- Nicholas W. Mathy
- Hongda Lu
-
Affiliations: Department of Oncology, Jianghan University School of Medicine, Wuhan, Hubei 430056, P.R. China, Creighton University School of Medicine, Omaha, NE 68178, USA, Department of Oncology, Wuhan Central Hospital, Wuhan, Hubei 430014, P.R. China - Published online on: April 23, 2018 https://doi.org/10.3892/mmr.2018.8922
- Pages: 8019-8030
-
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Wong MCS, Lao XQ, Ho KF, Goggins WB and Tse SLA: Incidence and mortality of lung cancer: Global trends and association with socioeconomic status. Sci Rep. 7:143002017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer Statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Penz E, Watt KN, Hergott CA, Rahman NM and Psallidas I: Management of malignant pleural effusion: Challenges and solutions. Cancer Manag Res. 9:229–241. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Shi H: Guidelines to the diagnosis and treatment of malignant pleural effusion. Chin J Intern Med. 53:166–167. 2014. | |
|
Zachary I: Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol. 280:C1375–C1386. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Ide AG, Baker NH and Warren SL: Vascularization of the brown pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am J Roentgenol. 42:891–899. 1939. | |
|
Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI | |
|
Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS and Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219:983–985. 1983. View Article : Google Scholar : PubMed/NCBI | |
|
Ferrara N and Henzel WJ: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 161:851–858. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N and Williams LT: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 255:989–991. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Harmey JH and Bouchier-Hayes D: Vascular endothelial growth factor (VEGF), a survival factor for tumor cells: Implications for anti-angiogenic therapy. Bioessays. 24:280–283. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Bradshaw M, Mansfield A and Peikert T: The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion. Curr Oncol Rep. 15:207–216. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zang J, Hu Y, Xu X, Ni J, Yan D, Liu S, He J, Xue J, Wu J and Feng J: Elevated serum levels of vascular endothelial growth factor predict a poor prognosis of platinum-based chemotherapy in non-small cell lung cancer. Onco Targets Ther. 10:409–415. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Popper HH: Progression and metastasis of lung cancer. Cancer Metastasis Rev. 35:75–91. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hu CP: Interpretation of expert consensus 2014 on diagnosis and treatment of malignant pleural effusion. J Transl Int Med. 3:1–2. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 20:4368–4380. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Fafliora E, Hatzoglou C, Gourgoulianis KI and Zarogiannis SG: Systematic review and meta-analysis of vascular endothelial growth factor as a biomarker for malignant pleural effusions. Physiol Rep. 4:e129782016. View Article : Google Scholar : PubMed/NCBI | |
|
Sriram KB, Relan V, Clarke BE, Duhig EE, Yang IA, Bowman RV, Lee YC and Fong KM: Diagnostic molecular biomarkers for malignant pleural effusions. Future Oncol. 7:737–752. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Gu Y, Zhang M, Li GH, Gao JZ, Guo L, Qiao XJ, Wang LH, He L, Wang ML, Yan L and Fu XH: Diagnostic values of vascular endothelial growth factor and epidermal growth factor receptor for benign and malignant hydrothorax. Chin Med J (Engl). 128:305–309. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou WB, Bai M and Jin Y: Diagnostic value of vascular endothelial growth factor and endostatin in malignant pleural effusions. Int J Tunerc Lung Dis. 13:381–386. 2009. | |
|
Nam HS: Malignant pleural effusion: Medical approaches for diagnosis and management. Tuberc Respir Dis (Seoul). 76:211–217. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y, Liang B, Zhao YJ, Wang SC, Fan YB and Wu GP: Transcription expression and clinical significance of vascular endothelial growth factor mRNA and endostatin mRNA in pleural effusions of patients with lung cancer. Diagn Cytopathol. 40:287–291. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang B, Wu GP, Zhao YJ and Wang SC: Transcription expression and clinical significance of TTF-1 mRNA in pleural effusion of patients with lung cancer. Diagn Cytopathol. 36:849–854. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Palaoro LA, Blanco AM, Gamboni M, Rocher AE and Rotenberg RG: Usefulness of ploidy, AgNor and immunocytochemistry for differentiating benign and malignant cells in serous effusions. Cytopathology. 18:33–39. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Light RW: Pleural effusions. Med Clin North Am. 95:1055–1070. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Liu QF: Clinical value of VEGF combined with CEA in the treatment of malignant pleural effusion of advanced NSCLC. Practical Oncol J (China). 27:156–159. 2013. | |
|
Stathopoulos GT and Kalomenidis I: Malignant pleural effusion: Tumor-host interactions unleashed. Am J Respir Crit Care Med. 186:487–492. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hamed EA, El-Noweihi AM, Mohamed AZ and Mahmoud A: Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusions. Respirology. 9:81–86. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Gerber HP and Ferrara N: Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 65:671–680. 2005.PubMed/NCBI | |
|
Numnum TM, Rocconi RP, Whitworth J and Barnes MN: The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol. 102:425–428. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med. 9:669–676. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Pritchard-Jones RO, Dunn DB, Qiu Y, Varey AH, Orlando A, Rigby H, Harper SJ and Bates DO: Expression of VEGF (XXX)b, the inhibitory isoforms of VEGF, in malignant melanoma. Br J Cancer. 97:223–230. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Fontanini G, Lucchi M, Vignati S, Mussi A, Ciardiello F, De Laurentiis M, De Placido S, Basolo F, Angeletti CA and Bevilacqua G: Angiogenesis as a prognostic indicator of survival in nonsmall-cell lung carcinoma: A prospective study. J Natl Cancer Inst. 89:881–886. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Ferrara N: Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev. 25:581–611. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Voelkel NF, Vandivier RW and Tuder RM: Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Moistiol. 290:L209–L221. 2006. View Article : Google Scholar | |
|
Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Mayerhofer M, Valent P, Sperr WR, Griffin JD and Sillaber C: BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia induciblefactor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood. 100:3767–3775. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Loeffler S, Fayard B, Weis J and Weissenberger J: Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. Int J Cancer. 115:202–213. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Cohen T, Nahari D, Cerem LW, Neufeld G and Levi BZ: Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem. 271:736–741. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Wójcik E, Jakubowicz J, Skotnicki P, Sas-Korzyńska B and Kulpa JK: IL-6 and VEGF in small cell lung cancer patients. Anticancer Res. 30:1773–1778. 2010.PubMed/NCBI | |
|
Yan J, Jiang Y and Xu H: Endu treatment of malignant pleural effusion. Practical J Cancer. 27:538–539. 2012. | |
|
O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:277–285. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Hayes AJ, Li LY and Lippman ME: Science, medicine, and the future. Antivascular therapy: A new approach to cancer treatment. BMJ. 318:853–856. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Xu X, Mao W, Chen Q, Zhuang Q, Wang L, Dai J, Wang H and Huang Z: Endostar, a modified recombinant human endostatin, suppresses angiogenesis through inhibition of Wnt/β-catenin signaling pathway. PLoS One. 9:e1074632014. View Article : Google Scholar : PubMed/NCBI | |
|
Rong B, Yang S, Li W, Zhang W and Ming Z: Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World J Surg Oncol. 10:1702012. View Article : Google Scholar : PubMed/NCBI | |
|
Mohajeri A, Sanaei S, Kiafar F, Fattahi A, Khalili M and Zarghami N: The challenges of recombinant endostatin in clinical application: Focus on the different expression systems and molecular bioengineering. Adv Pharm Bull. 7:21–34. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Shichiri M and Hirata Y: Antiangiogenesis signals by endostatin. FASEB J. 15:1044–1053. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Hajitou A, Grignet C, Devy L, Berndt S, Blacher S, Deroanne CF, Bajou K, Fong T, Chiang Y, Foidart JM and Noël A: The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J. 16:1802–1804. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Li DH, Liu QG, Wang HP, Yu M, Jiang J, Tang CH and Ning YL: Study on recombinant human endostatin in the treatment of malignant pleural effusion in the elderly. Shaanxi Med J. 44:1138–1139. 2015.(In Chinese). | |
|
Murakami A, Tabata C, Tabata R, Okuwa H and Nakano T: Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma. Oncol Lett. 3:581–585. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ma X, Yao Y, Yuan D, Liu H, Wang S, Zhou C and Song Y: Endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice. PLoS One. 7:e534492012. View Article : Google Scholar : PubMed/NCBI | |
|
Ishii H, Yazawa T, Sato H, Suzuki T, Ikeda M, Hayashi Y, Takanashi Y and Kitamura H: Enhancement of pleural treatment and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs). Lung Cancer. 45:325–337. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Prager GW, Lackner EM, Krauth MT, Unseld M, Poettler M, Laffer S, Cerny-Reiterer S, Lamm W, Kornek GV, et al: Targeting of VEGF dependent transendothelial migration of cancer cells by bevacizumab. Mol Oncol. 4:150–160. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Sun Y, Liu Y, Yu Q, Zhang Y, Li K, Zhu Y, Zhou Q, Hou M, Guan Z, et al: Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Zhongguo Fei Ai Za Zhi. 8:283–290. 2005.(In Chinese). PubMed/NCBI | |
|
Qin S, Yang L, Liang J, Cheng Y, Tan Q, Bi J, Wang L, Hu B, Shi J, Sun G, et al: Prospective, randomized, multicenter clinical study of endometrial and cisplatin in the treatment of malignant pleural effusion. Chin J Clin Oncol. 22:193–202. 2017.(In Chinese). | |
|
Hu X, Shi Y, Wang H, Zhang C, Liu P, Wang Y and Li J: A clinical study on intra-thoracic chemotherapy of recombinant human endostatin combined with cisplatin for malignant pleural effusion. Clin Med J. 3:23–27. 2015. | |
|
Wei H, Qin S, Yin X, Chen Y and Hua H: Endostar inhibits ascites formation and prolonged survival in mouse models of malignant ascites. Oncol Lett. 9:2694–2700. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Qin S, Liu X, Wang L, Chen Y, Qian J, Hui H, Gong X, Yang L and He Z: Clinical study of recombinant human endostatin combined with chemotherapy in the treatment of advanced malignant tumors of lung. Clin J Onol. 34:426–428. 2012.(In Chinese). | |
|
Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E, Fogler WE, Sim BK, Allred EN, Pirie-Shepherd SR and Folkman J: Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 61:7669–7674. 2011. | |
|
Shen H, Zhao J, Weng SS, Fang XF, Zhang YY and Huang JJ: Continuous administration of endostar plus GP chemotherapy in local advanced or metastatis lung squamous cell carcinoma. Acta Medica Mediterr. 32:57–62. 2016. | |
|
Qin M: Clinical observation of cisplatin plus endostar endovascular infusion in the treatment of advanced non-small cell lung cancer with malignant pleural effusion. China Pract Med. 11:228–229. 2016. | |
|
Xu J, Qi DL, Li XB and Wang RX: Recombinant human endostatin combined with chemotherapy in the treatment of malignant pleural effusion of non-small cell lung cancer. Chin J Clin Oncol. 24:1573–1576. 2014. | |
|
Huang L: Clinical observation on treatment of malignant pleural effusion of Non-small cell lung cancer with. Jilin Med. 35:4308–4309. 2014. | |
|
Yang Y, Lin R and Cao G: Combined with cisplatin in the treatment of malignant pleural effusion in non-small cell lung cancer. Chin Med. 22:21–22. 2013. | |
|
Liu W, Ham M, Yin N and Li J: Clinical study on the treatment of non-small cell lung cancer with malignant pleural effusion by intrapleural injection with. Shandong Pharmaceutical. 50:79–80. 2010. | |
|
Huang J: Observation on the therapeutic effect of Endu combined with cisplatin intrapleural injection on malignant pleural effusion. J Clin Med Practical. 13:63–64. 2010. | |
|
Li W: Observation of curative effect of intrapleural perfusion of malignant pleural effusion. J Med Forum. 32:170–172. 2011. | |
|
Tu J: Clinical study of recombinant human endostatin combined with intrapleural injection of cisplatin in the treatment of malignant pleural effusion of non-small cell lung cancer. Pract J Cancer. 12:1592–1594. 2014.(In Chinese). | |
|
Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, et al: BEYOND: A randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 33:2197–2204. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Shibuya M: Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti- and pro-angiogenic therapies. Genes Cancer. 2:1097–1105. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wu Z, Wu Q, Sun D, Wang Z, Shi Y and Dai G: Progress in response prediction for Bevacizumab in anti-tumor therapy. Prog Mod Bio. 14:4570–4573. 2014. | |
|
Guan F, Li Z, Yuan S and Gao J: Current status and clinical application of bevacizumab. Chin Sci. 12:302016. | |
|
Tamiya M, Tamiya A, Yamadori T, Nakao K, Asami K, Yasue T, Otsuka T, Shiroyama T, Morishita N, Suzuki H, et al: Phase 2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion. Med Oncol. 30:6762013. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu LH, Hsu PC, Liao TL, Feng AC, Chu NM and Kao SH: Pleural fluid osteopontin, vascular endothelial growth factor and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion: A prospective cohort study. BMC Cancer. 16:4632016. View Article : Google Scholar : PubMed/NCBI | |
|
Lin FH, Su WP and Jin R: Clinical study of bevacizumab combined with cisplatin in the treatment of malignant pleural effusion of non-small cell lung cancer. Clin J Clin Med. 44:698–700. 2010.(In Chinese). | |
|
Chi J, Bai Y and Chen H: Clinical study of bevacizumab combined with carboplatin in the treatment of malignant pleural effusion of non-small cell lung cancer. Chin J Clin Pharmacol. 13:1175–1180. 2016.(In Chinese). | |
|
Chen L and Xia SY: Effects and safety of bevacizumab combined with cisplatin in the treatment of malignant pleural effusion of non-small cell lung cancer. J Shanghai Jiaotong Univ. 8:1194–1198. 2015. | |
|
Qu B, Jiang W and Zhou Z: Clinical study of bevacizumab combined with cisplatin in the treatment of malignant pleural effusion of non-small cell lung cancer. J Chin Med Univ. 7:648–652. 2015.(In Chinese). | |
|
Huang B: Efficacy of bevacizumab combined with cisplatin in the treatment of malignant pleural effusion in non-small cell lung cancer. Intern J Resp Dis. 11:814–817. 2016. | |
|
Han N, Zhang MX, Yu SY and Cheng Y: Clinical study of bevacizumab combined with cisplatin/pemetrexed in the treatment of malignant pleural effusion of non-squamous cell carcinoma of non-squamous cell carcinoma. J Huazhong Univ Sci Tech. 5:588–591. 2013. | |
|
Liu HP, Gong CP, Qu L, Li X, Hu HT and Zhang YL: Efficacy of bevacizumab combined with cisplatin/pemetrexed in the treatment of malignant pleural effusion of non-small cell lung cancer. Med J Nat Defending Forces Southwest Chin. 12:1148–1151. 2016. | |
|
Lu J, Xie Q, Chen Q, Sun WH, Zhong AH, Shi Q, Liao SX and Zhu JX: The expression of BRMS1 in lung cancer and its effect on invasion and metastasis of lung cancer cells. J Clin Pulmonary Med. 9:1664–1667. 2016. | |
|
Usui K, Sugawara S, Nishitsuji M, Fujita Y, Inoue A, Mouri A, Watanabe H, Sakai H, Kinoshita I, Ohhara Y, et al: A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A. Lung Cancer. 99:131–136. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Masago K, Fujimoto D, Fujita S, Hata A, Kaji R, Ohtsuka K, Okuda C, Takeshita J and Katakami N: Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer. Mol Clin Oncol. 3:415–419. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tamiya M, Tamiya A, Yasue T, Nakao K, Omachi N, Shiroyama T, Tani E, Hamaguchi M, Morishita N, Suzuki H, et al: Vascular endothelial growth factor in plasma and pleural effusion is a biomarker for outcome after bevacizumab plus carboplatin-paclitaxel treatment for non-small cell lung cancer with malignant pleural effusion. Anticancer Res. 36:2939–2944. 2016.PubMed/NCBI | |
|
Gkiozos I, Tsagouli S, Charpidou A, Grapsa D, Kainis E, Gratziou C and Syrigos K: Levels of vascular endothelial growth factor in serum and pleural fluid are independent predictors of survival in advanced non-small cell lung cancer: Results of a prospective study. Anticancer Res. 35:1129–1137. 2015.PubMed/NCBI | |
|
Zhang Y, Yu LK, Lu GJ, Xia N, Xie HY, Hu W, Hao KK, Xu CH and Qian Q: Prognostic values of VEGF and Endostatin with malignant pleural effusions in patients with lung cancer. Asian Pac J Caner Prev. 15:8435–8440. 2014. View Article : Google Scholar | |
|
Hooper CE, Elvers KT, Welsh GI, Millar AB and Maskell NA: VEGF and sVEGFR-1 in malignant pleural effusions: Association with survival and pleurodesis outcomes. Lung Cancer. 77:443–449. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Sandler AB, Johnson DH and Herbst RS: Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res. 10:4258–4262. 2004. View Article : Google Scholar | |
|
Kitamura K, Kubota K, Ando M, Takahashi S, Nishijima N, Sugano T, Toyokawa M, Miwa K, Kosaihira S, Noro R, et al: Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion. Cancer Chemother Pharmacol. 71:457–461. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC, Rothman JM, et al: Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): An open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 18:1610–1623. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Assoun S, Brosseau S, Steinmetz C, Gounant V and Zalcman G: Bevacizumab in advanced lung cancer: State of the art. Future Oncol. 13:2515–2535. 2017. View Article : Google Scholar : PubMed/NCBI |
